Immunohistochemistry of folliculo-stellate cells in normal human adenohypophyses and in pituitary adenomas

Summary Presence and distribution of S-100 protein (S-100), neuron-specific enolase (NSE), cytokeratin polypeptides, glial fibrillary acidic protein (GFAP), vimentin, actin, lysozyme and pituitary hormones (prolactin, hGH, ACTH, -FSH, -LH, -TSH, alpha subunit) in folliculo-stellate cells (FSC) were studied in seven normal human pituitary glands and 28 pituitary adenomas using peroxidase-antiperoxidase and the avidin-biotin immunohistochemical techniques. Approximately 5% of the cells of the adenohypophysis were agranular, non-hormon-producing FSC most of which showed a conspicuous and strong reaction with S-100 antibodies but some were, in addition, GFAP- and vimentin-positive. In contrast to endocrine cells (EC), FSC were not decorated by antibodies to NSE or cytokeratins. In addition to supportive functions, these cells, due to their close special relationship to EC, seem to have transport and other metabolic functions yet to be elucidated. By their S-100 reactivity and their distribution FSC are comparable to glial cells of the central and schwann and satellite cells of the peripheral nervous system (PNS) as well as to supportive cells in neuroendocrine organs and related tumors (e.g., pheochromocytomas, paragangliomas, carcinoids). With one exception, S-100 reactive FSC were not found in pituitary adenomas. The immunohistochemical demonstration of S-100 protein in pituitary tissue is, therefore, a reliable aid in the discrimination between adenomas and normal pituitary tissue, particularly in small and poorly preserved specimens. In one adenoma FSC were found in addition to ACTH-producing tumor cells. This seems to be an extremely rare event suggesting a combination tumor.Supported in part by Fonds zur Förderung der wissenschaftlichen Forschung (no. 4708) to H. Denk     

人大肠癌中基质金属蛋白酶-7 mRNA的表达

目的:探讨基质金属蛋白酶-7(matrix metalloproteinase 7,MMP-7)与大肠癌浸润和转移的关系.方法:用逆转录聚合酶链式反应(RT-PCR)检测大肠癌和正常黏膜、炎性息肉、腺瘤及淋巴结中MMP-7 mRNA的表达.结果:97.4%(37/38)的大肠癌和1例肝转移中MMP-7 mRNA表达阳性,而相应正常黏膜几乎不表达;大肠癌中MMP-7 mRNA的表达水平随Dukes分期的进展而逐渐升高(P＜0.01),A期(0.28±0.08),B期(0.54±0.17),C期(0.55±0.09),D期(0.73±0.06).5例腺瘤MMP-7均为阳性,但表达水平低于癌组织(P＜0.01);3例炎性息肉均未见MMP-7表达.传统组织学检查有癌转移的13个淋巴结MMP-7表达均为阳性;组织学检查未见转移的12个淋巴结MMP-7表达6个阴性、6个阳性,再次行组织学检查于6个MMP-7阳性者中发现3个有微转移.结论:MMP-7的高表达可能在大肠癌的浸润和转移过程中具有重要作用;用RT-PCR方法检测淋巴结中MMP-7mRNA的表达是诊断大肠癌淋巴结微转移的敏感方法.     

碱性成纤维细胞生长因子与垂体腺瘤增殖及侵袭能力的关系

利用免疫组织化学方法检测 5 1例人类垂体腺瘤标本的碱性成纤维细胞生长因子 (bFGF)与增殖细胞核抗原 (PCNA)蛋白表达。结果显示 ,在 2 9例 (5 6 9% )垂体腺瘤标本中检测到bFGF呈中等强度以上的阳性表达 ;bFGF表达水平与PCNA标记指数呈正相关 ;在无功能腺瘤中 ,bFGF的表达与肿瘤侵袭性相关 ,但在激素分泌性腺瘤中两者相关性不明显。提示bFGF可能参与了垂体腺瘤的增殖过程及部分腺瘤的侵袭过程。     

结直肠锯齿状腺瘤的临床特征及恶变影响因素分析

目的锯齿状腺瘤被公认为结直肠癌的癌前病变,锯齿状通路被认为是可以独立发展成结直肠癌的重要通路,但目前对于锯齿状腺瘤恶变的相关危险因素还知之甚少。本文旨在分析锯齿状腺瘤在结直肠中的分布特点及潜在恶变因素。方法采用病例对照研究方法,回顾性收集2017年4月至2019年7月期间在中国医学科学院肿瘤医院行肠镜检查并经病理诊断为锯齿状腺瘤患者的临床资料,排除同时具有两种及以上病理类型病变的患者。总结锯齿状腺瘤的临床特征,并进行单因素和Logistic多因素回归分析,探讨锯齿状腺瘤发生恶变的影响因素。结果共在28730例行肠镜检查患者中,发现311例(1.08%)锯齿状腺瘤患者,共发现锯齿状腺瘤372枚。按WHO分类,无蒂锯齿状腺瘤/息肉22枚(5.9%),传统锯齿状腺瘤84枚(22.6%),未分类锯齿状腺瘤266枚(71.5%)。病理结果显示:无异型增生病变106枚(28.5%),低级别上皮内瘤变病变228枚(61.3%),高级别上皮内瘤变或癌变38枚(10.2%)。病变长径<10 mm有204枚(54.8%),≥10 mm有168枚(45.2%);病变位于左半结直肠238枚(64.0%),右半结肠134枚(36.0%)。内镜下大体分型:扁平型16枚(4.3%),无蒂型174枚(46.8%),亚蒂型117枚(31.5%),带蒂型59枚(15.9%)。窄带成像国际结直肠内镜(NICE)分型:Ⅰ型85枚(22.8%),Ⅱ型280枚(75.3%),Ⅲ型4枚(1.1%)。单因素分析显示,病变大小、病变位置、病变部位及不同WHO分类与结直肠锯齿状腺瘤发生恶变有关(均P<0.05);不同NICE分型的锯齿状腺瘤,其恶变率的差异亦有统计学差异(P=0.001)。多因素分析结果显示,病变长径≥10 mm(OR=6.699,95%CI:2.843~15.786)以及病变位于左半结直肠(OR=2.657,95%CI:1.042~6.775)是结直肠锯齿状腺瘤发生恶变的独立危险因素。结论锯齿状腺瘤主要位于左半结直肠,当病变长径≥10 mm或病变位于左半结直肠时,易发生恶变。     

阿帕替尼和替吉奥对结肠癌治疗效果的系统评价和Meta分析

目的通过系统评价和Meta分析探讨阿帕替尼与替吉奥对比治疗结肠癌的有效性和安全性。方法以"阿帕替尼""替吉奥""结肠癌""等为中文关键词,以"Apatinib""Tegafur""Colon cancer"等为英文关键词,检索PubMed,Cochrane Library,Embase,Web of Science,中国知网、中国生物医学文献服务系统、维普数据库、万方数据知识服务平台,时间限制在从建库到2020年12月。评价阿帕替尼和替吉奥对结肠癌的总体疗效,结肠癌进展和无进展生存期的差异。研究采用RevMan 5.3软件进行Meta分析。结果Meta分析结果显示,阿帕替尼与替吉奥对结肠癌的疗效相比,部分缓解+稳定的差异没有统计学意义(RR=1.10,95%CI,0.71~1.71,P=0.640),在结肠癌进展方面的差异没有统计学意义(RR=0.51,95%CI:0.28~1.32,P=0.205),在无进展生存期方面阿帕替尼组大于替吉奥组,差异具有统计学意义(SMD=0.90,95%CI;0.42~1.37,P<0.0001)。结论相较于替吉奥,阿帕替尼用于治疗结肠癌患者能明显延长无进展生存期,总体生存效益有所提高。     

腹腔镜右半结肠癌切除术后消化道重建的研究现状及前景

腹腔镜右半结肠癌切除术后腹腔内吻合正逐渐成为结直肠手术领域中的热点。研究者发现:腹腔内吻合与腹腔外吻合比较,前者在促进病人术后恢复,降低术后并发症发生率等方面有潜在优势。且腹腔内吻合较腹腔外吻合病人术后胃肠功能恢复更快、术后疼痛评分更低。但对于腹腔内吻合的并发症发生率,尤其是重要指标吻合口漏的比较,尚缺乏足够证据。而手术技术不统一、吻合口漏定义不明确是目前研究的主要困难。多项高质量的前瞻性随机对照试验目前正在进行中,对于腹腔镜右半结肠癌切除术的客观评价仍需要更高级别的循证医学证据验证。笔者综合分析国内外研究进展,系统阐述腹腔镜右半结肠癌切除术后消化道重建的研究现状及前景,旨在为我国结直肠外科临床研究探索新方向。     

利用CT表现鉴别肾上腺隐匿型嗜铬细胞瘤和皮质腺瘤

目的探讨如何利用CT表现对肾上腺隐匿型嗜铬细胞瘤和肾上腺皮质腺瘤进行鉴别诊断。方法收集2010年1月至2020年1月期间中国医科大学附属第一医院收治的177例肾上腺肿瘤患者进行回顾性分析,对比各组患者之间的一般临床资料和CT表现。结果隐匿型嗜铬细胞瘤56例、皮质醇腺瘤32例、醛固酮腺瘤44例、无功能腺瘤45例,隐匿型嗜铬细胞瘤组在肿瘤侧别上与无功能腺瘤组差异有统计学意义,在肿瘤最大直径、平扫CT值、动脉期和延迟期增强CT值上均显著大于三组肾上腺腺瘤组。以肿瘤直径≥2.95 cm诊断隐匿型嗜铬细胞瘤,曲线下面积(AUC)为0.872,敏感度为87.5%,特异性为76.0%;当平扫CT值≥24.5 Hu时,AUC为0.929,敏感度为94.0%,特异性为82.5%;当动脉期增强CT值≥89.5 Hu时,AUC为0.886,敏感度为72.7%,特异性为90.6%;当延迟期增强CT值≥82.5 Hu时,AUC为0.937,敏感度为84.6%,特异性为95.3%;联合以上四个指标时,AUC为0.981,阈值为≥0.118,敏感度为100%,特异性为90.6%。结论以肿瘤直径2.95 cm、平扫CT值24.5 Hu、动脉期增强CT值89.5 Hu和延迟期增强CT值82.5 Hu为阈值对肾上腺隐匿型嗜铬细胞瘤有较好的鉴别诊断价值。     

Multifocal Parotid Oncocytic Cystadenomatosis: A Rare Process that Can Mimic Malignancy

Multifocal cystic oncocytosis (MCO) is a rare, benign process accounting for approximately 0.1% of salivary gland lesions. Salivary oncocytosis is characterized by multiple unencapsulated solid nodules of oncocytic cells derived from transformed striated ducts. MCO is a variant of salivary oncocytosis which manifests as cystically dilated striated ducts. It is difficult to obtain a definitive preoperative diagnosis of MCO; therefore, these lesions are commonly treated with surgery. We report the unique case of a 66-year-old male who previously underwent a superficial left parotidectomy for a pleomorphic adenoma. Four years later, he presented with clinical and radiographic suspicion of a multifocal recurrent pleomorphic adenoma. The patient subsequently underwent a revision parotidectomy. However, final pathology confirmed a diagnosis of MCO. Although MCO is commonly treated with surgery due to lack of a definitive preoperative diagnosis, surgery is unnecessary outside of diagnostic, functional or cosmetic considerations. Thus, if a patient with parotid oncocytosis treated by superficial parotidectomy develops disease re-manifestation in the residual deep lobe, further surgery is not indicated. There is no risk of malignant progression in this process. We report on this unusual entity as it may mimic salivary malignancy or, as in this case, recurrence of benign disease.